Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$2.0 million.

  • Protagonist Therapeutics' Free Cash Flow rose 9292.77% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year decrease of 7220.56%. This contributed to the annual value of $182.8 million for FY2024, which is 35802.39% up from last year.
  • Protagonist Therapeutics' Free Cash Flow amounted to -$2.0 million in Q3 2025, which was up 9292.77% from -$29.6 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Free Cash Flow registered a high of $268.6 million during Q2 2024, and its lowest value of -$37.9 million during Q1 2022.
  • Over the past 5 years, Protagonist Therapeutics' median Free Cash Flow value was -$27.1 million (recorded in 2021), while the average stood at -$670842.1.
  • Over the last 5 years, Protagonist Therapeutics' Free Cash Flow had its largest YoY gain of 111703.59% in 2024, and its largest YoY loss of 27406.29% in 2024.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Free Cash Flow stood at -$27.1 million in 2021, then fell by 16.84% to -$31.7 million in 2022, then soared by 153.43% to $16.9 million in 2023, then tumbled by 274.06% to -$29.5 million in 2024, then skyrocketed by 93.13% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, -$29.6 million for Q2 2025, and $124.8 million during Q1 2025.